Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s claim that XOLAIR has a WARNING for anaphylaxis is directly supported by the provided FDA label text (Boxed Warning and Warnings/Precautions sections), including characteristic symptoms and monitoring/management instructions.
Category Scores
Accurate Statements
XOLAIR includes a Boxed Warning for anaphylaxis, described as a reported risk after administration with characteristic signs/symptoms and instructions to initiate in a healthcare setting and observe patients.
BOXED WARNING (Box) and Warnings and Precautions (5.1) provided in the prompt (initiate in healthcare setting; closely observe; symptoms including bronchospasm, hypotension, syncope, urticaria, and/or angioedema of throat or tongue).
The label further elaborates on anaphylaxis in Warnings and Precautions (5.1) and provides additional postmarketing safety details (6.2).
5.1 (Anaphylaxis) and 6.2 (Postmarketing Experience) provided in the prompt.
Unsupported Statements
Contradictions
Important Omissions
The response does not explicitly mention the label’s limitation-of-use statements indicating XOLAIR is not indicated for emergency treatment of allergic reactions/anaphylaxis (Sections 1.3 and 5.9).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is accurate and label-consistent regarding the presence of anaphylaxis warning/boxed warning; no contradictory safety assertions were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s explicit limitations-of-use stating XOLAIR is not indicated for emergency treatment of allergic reactions/anaphylaxis.
Suggested Improvement
When discussing anaphylaxis warnings, also note the label’s limitation-of-use/emergency treatment cautions from Sections 1.3 and 5.9.